Skip to main content
Shanghai Junshi Biosciences Co., Ltd. logo

Shanghai Junshi Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 1877 ISIN · CNE100003FF7 HKEX Manufacturing
Open in API
Filings indexed 1,740 across all filing types
Latest filing 2025-11-14 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 1877

About Shanghai Junshi Biosciences Co., Ltd.

http://www.junshipharma.com

Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company established in 2012. It is dedicated to the discovery, development, clinical research, and commercialization of innovative therapeutics, prioritizing the creation of first-in-class and best-in-class drugs. The company utilizes a global integrated R&D system and proprietary full life cycle antibody development platform technology to build a diversified and complementary pipeline. Junshi Biosciences operates as a full-chain entity, integrating research, production, and commercialization capabilities to maintain global competitiveness in the biopharmaceutical sector.

Recent filings

Filing Released Lang Actions
COMPLETION OF REGISTRATION OF THE FIRST GRANT OF A SHARE OPTIONS UNDER THE 2025 A SHARE OPTION INCENTIVE SCHEME
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Shanghai Junshi Biosciences Co., Ltd. regarding the completion of the registration of share options under an incentive scheme. It details the number of options, participants, exercise prices, and the impact on the company's financial condition. This type of disclosure regarding share-based incentive schemes and capital structure changes falls under the category of share issues or capital changes.
2025-11-14 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-11-14 English
OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON PROGRESS OF THE INCREASE IN SHAREHOLDING BY ONE OF THE CONTROLLING SHAREHOLDERS, ACTUAL CONTROLLERS AND THE CH
Director's Dealing Classification · 95% confidence The document is an 'Overseas Regulatory Announcement' from Shanghai Junshi Biosciences Co., Ltd. regarding the progress of a shareholding increase by the Chairman and controlling shareholder, Mr. Xiong Jun. It details specific transaction amounts, share counts, and the status of a previously announced share purchase plan. This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions by a company director/executive, or alternatively 'Regulatory Filings' (RNS). Given the specific nature of the disclosure regarding director/insider share accumulation, DIRS is the most precise classification.
2025-11-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings Classification · 85% confidence The document is a routine Monthly Return (Form FF301) filed to the Hong Kong Stock Exchange under Listing Rule Chapter 19B, detailing share capital and securities movements for October 2025. It is a regulatory return and does not announce a specific event like a new share issue, dividend, or management change. It falls into the general regulatory filings category rather than a standalone capital event or financial report. Therefore, it is classified as a Regulatory Filing (RNS).
2025-11-03 English
OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 2025 THIRD QUARTERLY REPORT
Interim / Quarterly Report Classification · 100% confidence The document is titled '2025 Third Quarterly Report' for Shanghai Junshi Biosciences Co., Ltd. It contains detailed financial statements, key accounting data, financial indicators, and shareholder information for the third quarter of 2025. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2025
2025-10-28 English
VOLUNTARY ANNOUNCEMENT - WHOLLY-OWNED SUBSIDIARY PASSING FDA ON-SITE INSPECTION
Regulatory Filings Classification · 90% confidence The document is a voluntary announcement by Shanghai Junshi Biosciences concerning its wholly-owned subsidiary passing an FDA on-site inspection. It is a general operational/regulatory update disclosed via the Hong Kong Exchange format, not a financial report, earnings release, board change, capital action, or other specific category. It does not present financial results, voting matters, or share transactions, so it falls into the fallback “Regulatory Filings” category.
2025-10-22 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.